XNAS · Healthcare · Biotechnology
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 0.21 | 0.32 | +52.38% | $288.8M | ✅ Beat | -3.76% | -0.26% | — |
| 2026-02-11 | Q4 2025 | -0.06 | -0.64 | -966.67% | $288.1M | ❌ Miss | -2.93% | +2.41% | +2.03% |
| 2025-11-12 |
| Q3 2025 |
| -0.41 |
| -1.17 |
| -185.12% |
| $249.8M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -1.42 | -0.93 | +34.51% | $179.2M | ✅ Beat | +0.00% | +0.89% | +8.17% |
| 2025-02-12 | Q4 2024 | -1.20 | -0.68 | +43.33% | $185.6M | ✅ Beat | +12.96% | +22.97% | +21.28% |
| 2024-11-14 | Q3 2024 | -1.52 | -1.89 | -24.34% | $63.6M | ❌ Miss | +1.79% | -1.32% | +9.91% |
| 2024-09-03 | Q2 2024 | -1.56 | -2.06 | -32.05% | $38.8M | ❌ Miss | -11.27% | -14.79% | +4.66% |
| 2024-05-02 | Q1 2024 | — | -2.50 | — | $104.1M | — | -2.76% | -5.65% | -4.10% |
Showing last 8 quarters.